Chemotherapy- and Immune-Related Gene Panel in Prognosis Prediction and Immune Microenvironment of SCLC

Overview

Journal Front Cell Dev Biol

Specialty Cell Biology

Date 2022 Jul 5

PMID 35784467

Authors

Meng-Yu Chen

Yue-Can Zeng

Xi-He Zhao

Affiliations

Soon will be listed here.

Abstract

Small-cell lung cancer (SCLC) is a highly proliferative, invasive lung cancer with poor prognosis. Chemotherapy is still the standard first-line treatment for SCLC, but many patients relapse due to chemoresistance. Along with advances in immunology, it is essential to investigate potential indicators of the immune response and the prognosis of SCLC. Using bioinformatics analysis, we identified 313 differentially expressed genes (DEGs) in SCLC and normal lung samples, and we found that four upregulated genes (, , , and ) were associated with platinum resistance, while immune-related genes (HLA family genes) were downregulated in SCLC. Then, a prognostic prediction model was constructed for SCLC based on those genes. Immune cell infiltration analysis showed that antigen presentation was weak in SCLC, and expression was negatively correlated with CD8+ T cells, while expression was positively correlated with M1 macrophages, memory B cells, and CD8+ T cells. We also found that was related to poor prognosis and inversely correlated with , which was verified with immunohistochemical staining in 151 SCLC specimens. Our study findings indicated that may be a potential prognosis indicator and a target to reverse the immunosuppressive tumor microenvironment of SCLC.

Citing Articles

A 15-Gene-Based Risk Signature for Predicting Overall Survival in SCLC Patients Who Have Undergone Surgical Resection.

Atay S Cancers (Basel). 2023; 15(21).

PMID: 37958393 PMC: 10649828. DOI: 10.3390/cancers15215219.

Deciphering the immunological and prognostic features of bladder cancer through platinum-resistance-related genes analysis and identifying potential therapeutic target P4HB.

Xiong S, Li S, Zeng J, Nie J, Liu T, Liu X Front Immunol. 2023; 14:1253586.

PMID: 37790935 PMC: 10544894. DOI: 10.3389/fimmu.2023.1253586.

References

Smoot M, Ono K, Ruscheinski J, Wang P, Ideker T . Cytoscape 2.8: new features for data integration and network visualization. Bioinformatics. 2010; 27(3):431-2. PMC: 3031041. DOI: 10.1093/bioinformatics/btq675. View

Jain M, Zhang L, He M, Zhang Y, Shen M, Kebebew E . TOP2A is overexpressed and is a therapeutic target for adrenocortical carcinoma. Endocr Relat Cancer. 2013; 20(3):361-70. PMC: 4990817. DOI: 10.1530/ERC-12-0403. View

Cao Y, Zhang G, Wang P, Zhou J, Gan W, Song Y . Clinical significance of UGT1A1 polymorphism and expression of ERCC1, BRCA1, TYMS, RRM1, TUBB3, STMN1 and TOP2A in gastric cancer. BMC Gastroenterol. 2017; 17(1):2. PMC: 5217235. DOI: 10.1186/s12876-016-0561-x. View

Cai L, Liu H, Huang F, Fujimoto J, Girard L, Chen J . Cell-autonomous immune gene expression is repressed in pulmonary neuroendocrine cells and small cell lung cancer. Commun Biol. 2021; 4(1):314. PMC: 7943563. DOI: 10.1038/s42003-021-01842-7. View

Gazdar A, Carney D, Nau M, Minna J . Characterization of variant subclasses of cell lines derived from small cell lung cancer having distinctive biochemical, morphological, and growth properties. Cancer Res. 1985; 45(6):2924-30. View

Zheng H, Li X, Chen C, Chen J, Sun J, Sun S . Quantum dot-based immunofluorescent imaging and quantitative detection of TOP2A and prognostic value in triple-negative breast cancer. Int J Nanomedicine. 2016; 11:5519-5529. PMC: 5085300. DOI: 10.2147/IJN.S111594. View

Gazdar A, Bunn P, Minna J . Small-cell lung cancer: what we know, what we need to know and the path forward. Nat Rev Cancer. 2017; 17(12):725-737. DOI: 10.1038/nrc.2017.87. View

Horn L, Mansfield A, Szczesna A, Havel L, Krzakowski M, Hochmair M . First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. N Engl J Med. 2018; 379(23):2220-2229. DOI: 10.1056/NEJMoa1809064. View

Liu D, Huang C, Kameyama K, Hayashi E, Yamauchi A, Sumitomo S . Topoisomerase IIalpha gene expression is regulated by the p53 tumor suppressor gene in nonsmall cell lung carcinoma patients. Cancer. 2002; 94(8):2239-47. DOI: 10.1002/cncr.10450. View

10.

Sato T, Kaneda A, Tsuji S, Isagawa T, Yamamoto S, Fujita T . PRC2 overexpression and PRC2-target gene repression relating to poorer prognosis in small cell lung cancer. Sci Rep. 2013; 3:1911. PMC: 3665955. DOI: 10.1038/srep01911. View

11.

Mak D, Li S, Minchom A . Challenging the recalcitrant disease-developing molecularly driven treatments for small cell lung cancer. Eur J Cancer. 2019; 119:132-150. DOI: 10.1016/j.ejca.2019.04.037. View

12.

Chowell D, Morris L, Grigg C, Weber J, Samstein R, Makarov V . Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. Science. 2017; 359(6375):582-587. PMC: 6057471. DOI: 10.1126/science.aao4572. View

13.

Delgado J, M Martinez L, Sanchez T, Ramirez A, Iturria C, Gonzalez-Avila G . Lung cancer pathogenesis associated with wood smoke exposure. Chest. 2005; 128(1):124-31. DOI: 10.1378/chest.128.1.124. View

14.

Jiang L, Huang J, Higgs B, Hu Z, Xiao Z, Yao X . Genomic Landscape Survey Identifies SRSF1 as a Key Oncodriver in Small Cell Lung Cancer. PLoS Genet. 2016; 12(4):e1005895. PMC: 4836692. DOI: 10.1371/journal.pgen.1005895. View

15.

Chin C, Chen S, Wu H, Ho C, Ko M, Lin C . cytoHubba: identifying hub objects and sub-networks from complex interactome. BMC Syst Biol. 2014; 8 Suppl 4:S11. PMC: 4290687. DOI: 10.1186/1752-0509-8-S4-S11. View

16.

Gay C, Stewart C, Park E, Diao L, Groves S, Heeke S . Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell. 2021; 39(3):346-360.e7. PMC: 8143037. DOI: 10.1016/j.ccell.2020.12.014. View

17.

Borromeo M, Savage T, Kollipara R, He M, Augustyn A, Osborne J . ASCL1 and NEUROD1 Reveal Heterogeneity in Pulmonary Neuroendocrine Tumors and Regulate Distinct Genetic Programs. Cell Rep. 2016; 16(5):1259-1272. PMC: 4972690. DOI: 10.1016/j.celrep.2016.06.081. View

18.

Challa-Malladi M, Lieu Y, Califano O, Holmes A, Bhagat G, Murty V . Combined genetic inactivation of β2-Microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma. Cancer Cell. 2011; 20(6):728-40. PMC: 3660995. DOI: 10.1016/j.ccr.2011.11.006. View

19.

Pabla N, Ma Z, McIlhatton M, Fishel R, Dong Z . hMSH2 recruits ATR to DNA damage sites for activation during DNA damage-induced apoptosis. J Biol Chem. 2011; 286(12):10411-8. PMC: 3060494. DOI: 10.1074/jbc.M110.210989. View

20.

von Pawel J . The role of topotecan in treating small cell lung cancer: second-line treatment. Lung Cancer. 2003; 41 Suppl 4:S3-8. DOI: 10.1016/s0169-5002(03)90519-8. View